Daily Rifapentine for Treatment of Pulmonary Tuberculosis. A Randomized, Dose-Ranging Trial
Susan E. Dorman(Johns Hopkins University), Marc Weiner(The University of Texas at San Antonio Health Science Center), Payam Nahid(San Francisco General Hospital), Grace Muzanyi(The University of Texas at San Antonio Health Science Center), Stefan Goldberg, Jason E. Stout(Duke University), Neil W. Schluger(Columbia University), John L. Johnson(University of Pennsylvania), Radojka M. Savić(The University of Texas at San Antonio Health Science Center), Andrew Vernon(Centers for Disease Control and Prevention), William R. Mac Kenzie(Georgia Department of Public Health), Lorna Bozeman(Centers for Disease Control and Prevention), Charles M. Heilig(Centers for Disease Control and Prevention), Emily J. Hecker(Duke University), Eric Nuermberger(Johns Hopkins University), Pei-Jean I. Feng(Centers for Disease Control and Prevention), Ruth N. Moro(Centers for Disease Control and Prevention), Kelly E. Dooley(Johns Hopkins University)
American Journal of Respiratory and Critical Care Medicine
December 9, 2014
Cited by 112
Related Papers
Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis
|Clinical Infectious Diseases|2016|1.5k
Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010.
|PubMed|2010|1.1k